Cygene Laboratories Inc. announced that it is introducing an alcohol-dependence genetic profile product for the Eurasian market. The new alcohol-dependence product analyzes variations in seven genes known to be associated with an increased risk for excessive alcohol consumption, substance abuse and some of the related complications with these behaviors. It is targeted geographically to the Eurasian market, because the genes chosen for the test panel relate to the ethnic composition of the region. CyGene currently markets a variety of DNA predictive genetic test panels that provide consumers with information on genetic predisposition to treatable conditions. CyGene is the only consumer genetic testing provider that guarantees anonymity to its customers, while providing access to the most updated science at the lowest possible price. The new Alcohol Dependence DNA Analysis is priced at $130 retail. Distributors are being recruited throughout the region and are invited to contact CyGene for information on how they can participate in the sale of CyGene's products.

Cygene Laboratories Inc. announced that its direct-to-consumer predictive genetic products have been introduced in the Russian Federation by its exclusive licensee CyGene Russia, LLC. The CyGene products are the first predictive DNA tests for the Russian market. CyGene currently markets a variety of DNA predictive genetic test panels that provide consumers with information on genetic predisposition to treatable conditions. CyGene is the only consumer genetic testing provider that guarantees anonymity to its customers, while providing access to the most updated science at the lowest possible price.

On February 22, 2008, Cygene Laboratories Inc. filed a Certificate of Amendment of the Certificate of Incorporation with the Secretary of State of the State of Delaware. The Certificate of Amendment, formally approved by the Company’s stockholders pursuant to a special meeting of the stockholders held on February 21, 2008, amended the Company’s Certificate of Incorporation to increase the number of authorized common stock, par value $0.001, from 75,000,000 shares to 200,000,000 shares.